Cannabis is an ancient medicinal herb that has been used for thousands of years to treat nausea, vomiting, pain and other ailments. Cannabis has also been used to stimulate appetite, improve sleep and alleviate depression. Recently, cannabis has renewed research interest for its use in the management and treatment of several oncology-related symptoms. As a result, Cannabis is moving from the fringes of alternative medicine to the forefront, as research intensifies to find and study its therapeutic properties. From alleviating nausea associated with chemotherapy to relieving chronic pain, which one of these actually work? What are some potential side effects?
Chemotherapy-induced Nausea and Vomiting (CINV)
"Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy" published in 2015 is a thorough meta-analysis of 23 random controlled trials that looked at whether CBD actually helped solve nausea and vomiting for cancer patients receiving chemotherapy. What they found was that CBD can significantly reduce vomiting in patients when compared to placebos and that CBD is as effective as traditional anti-nausea or anti-emetic drugs. You can click here to read a detailed summary of the study delving into the impact of CBD on nausea & vomiting.
Analgesia or Pain Relief
Most cancer patients experience pain of some sort. This could be pain due to chemotherapy, radiation treatment, or the disease itself. As a result, doctors have started prescribing opioids which have their own list of side effects such as sedation, respiratory depression, constipation, nausea/vomiting, and dependence/addiction.
In the study, "Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain", Johnson et al use a randomized controlled trial to study the impact of THC:CBD extract, THC extract, or placebo on pain for cancer patients. They found a significant decrease in pain compared to the placebo for the THC:CBD group but not for the THC only group. 43% of the THC:CBD group saw a 30% improvement in pain. Based on this finding, Johnson et al recommended the use of this THC:CBD extract for pain relief for advanced cancer patients when traditional opioids don't work.
As a speculative side note, the THC:CBD extract may have worked when the THC alone did not work because of the entourage effect of full spectrum CBD. But what does Full Spectrum CBD mean? Basically, it is a CBD extract that contains the full spectrum – or full range – of extracts that occur naturally in the cannabis plant. Research has shown that the chemical compounds in Cannabis work differently (and better) together rather than individually. This is called the entourage effect. Thus, the THC:CBD extract may be interacting together to cause the entourage effect where the THC could not work individually.
In their paper, "The Efficacy of Medical Marijuana in the Treatment of Cancer-Related Pain", Pawasarat et al showed that patients significantly reduced their use of Morphine Milliequivalent (MME) when they used medical cannabis. This study may show that medical cannabis may also help in increasing the effectiveness of opioids and thus delay the development of an opioid dependance.
Cachexia or Wasting Syndrome
In a study of 469 advanced cancer patients, Jatoi et al found that megestrol acetate was superior in inducing appetite when compared to the tetrahydrocannabinol, Dronabinol. Dronabinol (THC) has been used as by AIDS patients since 1985 when it was first approved by the US FDA to help with anorexia in AIDS patients.
Tumor Suppressor
This is probably the most controversial use of medical cannabis. One should also keep in mind that, even if we read promising results in these studies, we should not interpret them to mean that every cancer cell line will have the same positive response.
Dr. Baram et al. studied the impact of CBD extracts on 12 different forms of cancer. Results varied depending on the type of cancer and THC was shown to have an impact on cell death in a few cases. In the end, the researchers concluded that a combination of cannabinoids may be the key behind the effectiveness of certain therapies instead of the presence or amount of THC. Therefore, they recommend the use of full spectrum cannabinoid therapy instead of isolating THC. You can read this comprehensive guide on Full Spectrum CBD to learn more.
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments.
Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others.
The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others.
The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58According to this study, over the next five years the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market will register a 5.9% CAGR in terms of revenue, the global market size will reach US$ 96 million by 2024, from US$ 72 million in 2019.
In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business, shared in Chapter 3.This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.This study considers the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs value and volume generated from the sales of the following segments:Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.5-HT3 InhibitorsNK1 InhibitorsOtherSegmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.Highly Emetogenic ChemotherapyModerately Emetogenic ChemotherapyLow Emetogenic ChemotherapyOtherThis report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaSpainMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC CountriesThe report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.
The key manufacturers covered in this report: Breakdown data in in Chapter 3.MerckEisaiMundipharmaQilu PharmaTevaNovartisHeron TherapeuticsRocheMylanTesaroResearch objectives:To study and analyze the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by identifying its various subsegments.Focuses on the key global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58Table of content1 Scope of the Report1.1 Market Introduction1.2 Research Objectives1.3 Years Considered1.4 Market Research Methodology1.5 Economic Indicators1.6 Currency Considered2 Executive Summary2.1 World Market Overview2.1.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption 2014–20242.1.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption CAGR by Region2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Type2.2.1 5-HT3 Inhibitors2.2.2 NK1 Inhibitors2.2.3 Other2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption by Type2.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Market Share by Type (2014–2019)2.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue and Market Share by Type (2014–2019)2.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sale Price by Type (2014–2019)2.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Application2.4.1 Highly Emetogenic ChemotherapyCONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
The global Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented by company, region (country), by Type, and by Application.
Players, stakeholders, and other participants in the global Chemotherapy-Induced Nausea and Vomiting Drugs market will be able to gain the upper hand as they use the report as a powerful resource.
The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by TypeDownload FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapyinduced-nausea-vomiting-drugs-2021-715 Existing DrugsAkynzeo (Netupitant-Palonosetron FDC)Aloxi (Palonosetron)Emend (Aprepitant)Kytril Generic (Granisetron)Zofran Generic (Ondansetron)Pipeline DrugsSUSTOL (Granisetron Injection extended release)Rolapitant Segment by Application Serotonin Receptor AntagonistsNK1 Receptor Antagonists The Chemotherapy-Induced Nausea and Vomiting Drugs market is analysed and market size information is provided by regions (countries).
Segment by Application, the Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company Merck & Co., Inc.GlaxoSmithKline plcTesaro, Inc.Helsinn GroupF.
Chemotherapy-Induced Nausea and Vomiting Therapeutics Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the chemotherapy-induced nausea and vomiting therapeutics market include GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceuticals, Heron Therapeutics, Inc., F. Hoffmann-La Roche AG, Tesaro, Inc., Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/chemotherapy-induced-nausea-and-vomiting-therapeutics-market/download-sampleMarket DynamicsRising cancer prevalence, a growing number of patients undergoing chemotherapy, expanding healthcare infrastructure, and a high success rate of therapies are factors accelerating the demand for nausea and vomiting drugs induced by chemotherapy.
As per World Health Organization (WHO) estimates, cancer is a leading cause of death worldwide, accounting for nearly 10 million new cases in 2020.
Easing the health insurance process, expanding the number of cancer specialist hospitals worldwide, and growing life expectancy is causing a rise in the number of chemotherapies performed, propelling the market growth.
